FDA 483 - Siegfried Pharma AG - December 13, 2019

From December 9 to December 13, 2019, the U.S. Food and Drug Administration (FDA) conducted an inspection of the Siegfried Pharma AG manufacturing facility located in Zofingen, Switzerland. This assessment identified several critical deficiencies in the site’s laboratory controls, equipment maintenance, and quality oversight systems.

Primary violations included inadequate laboratory testing for drug impurities, where analytical methods were stopped prematurely, potentially failing to account for all total impurities in tablets distributed to the U.S. market. Additionally, dissolution testing was found to be poorly documented, lacking recorded start and end times as well as verification of media temperatures. Investigators also observed that manufacturing equipment was not properly maintained; some surfaces had scratches and dents that hindered effective cleaning, while other machinery tagged as "clean" still contained visible stains and residues. Furthermore, the firm failed to follow written procedures for annual product quality reviews, as several documented deviations and change controls were omitted from official reports until the inspection began.

These findings were issued as inspectional observations rather than a final agency determination. Within the regulatory framework of pharmaceutical manufacturing safety and quality, Siegfried Pharma AG is required to respond to the FDA. The company must provide a detailed corrective action plan addressing these deficiencies or submit objections to the observations. Failure to rectify these issues could lead to further regulatory action to ensure the safety and purity of products exported to the United States.